Suvratoxumab

Drug Profile

Suvratoxumab

Alternative Names: Human immunoglobulin G1 kappa monoclonal antibody; MEDI-4893

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biosynexus; GlaxoSmithKline; Regeneron Pharmaceuticals
  • Developer MedImmune
  • Class Anti-infectives; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia
  • No development reported Staphylococcal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Staphylococcal-infections in USA (IV, Infusion)
  • 22 Apr 2017 Pharmacodynamics data from a preclinical trial in Staphylococcal infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 08 Sep 2014 Phase-II clinical trials in Nosocomial pneumonia (Prevention) in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top